Fig. 2From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyondPhase 1 trials by year and type of studies, 2010–2020. ADC antibody–drug conjugate, BiTE bispecific antibody, CAR-T chimeric antigen receptor T cell, MoAb monoclonal antibody, Small small molecule inhibitor/modulator. Therapies not categorized as one of the above were excluded (59/363, 16%)Back to article page